Overcoming the many known barriers to adopting and implementing an RBM program.
Every day, the internet is used to perform countless transactions. While the internet may seem limitless, the technology, itself, is flawed in that it is not capable of assigning actual ownership of the transacted item, or asset.
It’s been nearly two decades since Electronic Data Capture (EDC) technology was introduced into clinical trials – one of the first significant steps in automating the trial process. Now, with the availability of robotic process automation (RPA), cognitive analytics, and artificial intelligence (AI), it’s time to press on with further digitalisation of clinical development.
How integrating mHealth can transform medical product pipelines and the patient care continuum.
When implementing a randomization and trial supply management (RTSM) system for a clinical trial, there is a shared responsibility between the RTSM vendor and sponsor organizations to ensure the system performs as intended according to predefined requirements.
Software solutions provider adds value for a midsize pharmaceutical company from a quality, cost and study governance perspective by enabling them to implement risk-based (dynamic) approaches to monitoring.
To enable the completion of clinical trials as safely, efficiently and quickly as possible, PerkinElmer Informatics’ clinical solutions streamline clinical trial data visualization and analysis with real-time access to clinical data in all phases of clinical development.
Learn how PerkinElmer’s clinical solutions give clinical operations organizations the unprecedented ability to reduce the time, cost and risk of running clinical trials while accelerating the time to market for products across the entire portfolio of clinical candidates.
Achieve clinical trial operations excellence using this an innovative solution that gives clinical operations organizations the unprecedented ability to reduce the time, cost, and risk of running clinical trials while accelerating time to market for products across the entire portfolio of clinical candidates.
Gilead Sciences’ previous studies of Ranexa (ranolazine) relied on data from exercise treadmill parameters as the primary endpoint. But collecting data in this manner is costly, logistically challenging, and bears questionable clinical relevance — especially at the individual patient level. Learn how Gilead Sciences successfully utilized ERT handhelds to collect regulatory-compliant, patient-driven data in support of the primary efficacy endpoint in a Phase IV study of Ranexa.